Upcoming Conference

REGISTRATION IS OPEN NOW!
On 12- 14 November 2019 ReSViNET Foundation will host its 5th conference: “RSVVW 2019 - A Global Conference on Novel RSV Preventive and Therapeutic Interventions" in Accra, Ghana. ​
ReSViNET Foundation is certified by NGOsource as equivalent to a U.S. public charity!

RESPIRATORY SYNCYTIAL VIRUS AND
​CHILD PNEUMONIA WEBINAR

Visual
Use the link below to access the SlideShare presentation for the talks:
https://www.slideshare.net/secret/H0MzMgF2seNUX7
 NOTE: Please download this slide deck from the SlideShare platform to view.
Listen to talks by:
  • Dr. Ting Shi (University of Edinburgh): Global disease burden estimate of RSV in young children
  • Dr. Marijke Proesmans (Katholieke Universiteit Leuven): RSV therapeutics
  • Dr. Keith Klugman (Director, Pneumonia, Bill&Melinda Gates Foundation): RSV immunization and future directions
  • Dr. Louis Bont (Chairman ReSViNET Foundation): RSV clinical presentation and disease severity​

Recent RESVINET PUBLICATIONs

EXPERT CONSENSUS ON PALIVIZUMAB USE FOR RESPIRATORY SYNCYTIAL VIRUS IN DEVELOPED COUNTRIES
Sánchez Luna M, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A, Chawla R, Dotta A, Rodríguez Fernández R, Resch B, Carbonell-Estrany X.
Abstract
Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early childhood and palivizumab is the only licensed intervention for prevention. Palivizumab guidelines should reflect the latest evidence, in addition to costs-effectiveness and healthcare budgetary considerations. RSV experts from Europe, Canada and Israel undertook a systematic review of the evidence over the last 5 years and developed recommendations regarding prophylaxis in industrialised countries. ..read more

Educational activities

PeerVoice has launched three RSV activities, in collaboration with and endorsed by ReSViNET Foundation. Use the link below for more information and content of the programs.
RSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries. 
Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission with the goal to decrease the global burden of RSV infection through the advancement of research; providing scientific input and involvement in clinical trials. ReSViNET Foundation is a financially and otherwise independent regulated entity.

ABOUT RESVINET FOUNDATION

PAPER OF THE MONTH

Complete RSV antibody repertoire at birth in preemies.
Pou C, Nkulikiyimfura D, Henckel E, Olin A, Lakshmikanth T, Mikes J, Wang J, Chen Y, Bernardsson AK, Gustafsson A, Bohlin K, Brodin P. 

Virscan is a novel diagnostic tool to measure antibodies against >1000 viral strains. It shows previous viral exposures of an individual person. Christian Pou and colleagues used Virscan to get understand antibody transfer from mothers to their infants. The authors compared the antibody repertoire against RSV, amongst other viruses, of preterm and term infants. Despite a higher IgG concentration in term infants, both groups had the same antibody repertoire. Furthermore, the RSV-neutralizing capacity in plasma of preterm and term infants did not differ. This is surprising because it’s is generally accepted that maternal antibody transfer occurs in the third trimester, and that extremely premature children lack this passive immunity and therefor are more prone to develop RSV. It’s fascinating that preterm infants would have the same repertoire and functionally active RSV-antibodies as term infants. Nevertheless, it leaves us with the question what the precise role is of maternal RSV antibodies in RSV immunity in preterm infants. As the number of participants in this complex study was low, future research should aim to confirm these findings and help us understand transfer of specific vaccine-induced antibodies.

ReSViNET Global partners